Patents by Inventor Somasekhar Bhamidipati

Somasekhar Bhamidipati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRICYCLIC CARBAMATE JAK INHIBITORS
    Publication number: 20110269749
    Abstract: The present disclosure relates to 2,4-pyrimidinediamines substituted with tricyclic carbamates and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, such as JAK2 or JAK3, is therapeutically useful.
    Type: Application
    Filed: September 23, 2009
    Publication date: November 3, 2011
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Vadim Markovtsov
  • Prodrugs of 2,4-pyrimidinediamine compounds and their uses
    Patent number: 7989448
    Abstract: The present disclosure provides compounds of the following formula, and methods of using the compounds to inhibit cellular degranulation and to treat diseases associated therewith.
    Type: Grant
    Filed: November 10, 2008
    Date of Patent: August 2, 2011
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Esteban Masuda
  • PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
    Publication number: 20110144059
    Abstract: The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, salts and hydrates of the prodrugs, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications.
    Type: Application
    Filed: November 20, 2007
    Publication date: June 16, 2011
    Inventors: Somasekhar Bhamidipati, Rajinder Singh, Thomas Sun, Esteban Masuda
  • 2,4-Pyrimidinediamine Compounds and their Uses
    Publication number: 20110144330
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Application
    Filed: January 21, 2011
    Publication date: June 16, 2011
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Rajinder SINGH, Ankush ARGADE, Donald PAYAN, Susan MOLINEAUX, Sacha J. HOLLAND, Jeffrey CLOUGH, Holger KEIM, Somasekhar BHAMIDIPATI, Catherine SYLVAIN, Hui LI, Alexander B. ROSSI
  • 2,4-Pyrimidinediamine Compounds and Prodrugs and Their Uses
    Publication number: 20110124599
    Abstract: The present disclosure provides biologically active 2,4-pyrimidinediamine compounds of formulae (I)-(III): and salts thereof, compositions comprising these compounds, and methods of using these compounds in a variety of applications.
    Type: Application
    Filed: November 19, 2010
    Publication date: May 26, 2011
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Rajinder Singh, Somasekhar Bhamidipati, Jeffrey Clough
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 7947698
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: May 24, 2011
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Andy Atuegbu, Vadim Markovtsov, Somasekhar Bhamidipati, Rajinder Singh, Vanessa Taylor, Sambaiah Thota, Jeffrey Wayne Clough, David Carroll, Hui Li, Robin Cooper
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20110082146
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: December 13, 2010
    Publication date: April 7, 2011
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Andy Atuegbu, Vadim Markovtsov, Somasekhar Bhamidipati, Rajinder Singh, Vanessa Taylor, Sambaiah Thota, Jeffrey Wayne Clough, David Carroll, Hui Li, Robin Cooper
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 7915273
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: February 24, 2010
    Date of Patent: March 29, 2011
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Ankush Argade, Arvinder Sran, David Carroll, Jeffrey Clough, Kin Tso, Somasekhar Bhamidipati, Sambaiah Thota, Rajinder Singh, Vanessa Taylor, Hui Li, Esteban Masuda
  • 2,4-pyrimidinediamine compounds and their uses
    Patent number: 7906644
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: March 15, 2011
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20110027856
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: October 11, 2010
    Publication date: February 3, 2011
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Hui Li, Vanessa Taylor, Somasekhar Bhamidipati, John Ramphal, Kin Tso, Arvinder Sran, Holger Keim, Vadim Markovtsov, David Carroll, Sambaiah Thota, Ankush Argade, Jeffrey Wayne Clough, Rajinder Singh, Robin Cooper
  • Deuterated 2, 4-Pyrimidinediamine Compounds and Prodrugs Thereof and Their Uses
    Publication number: 20110015155
    Abstract: The present disclosure provides biologically active deuterated 2,4-pyrimidinediamine compounds and prodrugs thereof, compositions comprising the deuterated compounds, intermediates and methods for synthesizing the deuterated compounds and methods of using the deuterated compounds in a variety of applications.
    Type: Application
    Filed: July 16, 2010
    Publication date: January 20, 2011
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Somasekhar Bhamidipati, Rajinder Singh, Jeffrey Clough
  • Compositions and methods for inhibition of the JAK pathway
    Patent number: 7834024
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: November 16, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Hui Li, Vanessa Taylor, Somasekhar Bhamidipati, John Ramphal, Kin Tso, Avinder Sran, Holger Keim, Vadim Markovtsov, David Carroll, Sambaiah Thota, Ankush Argade, Jeffrey Wayne Clough, Rajinder Singh, Robin Cooper
  • N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines
    Patent number: 7825116
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: November 2, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li
  • 2,4-pyrimidinediamine compounds and their uses
    Patent number: 7820819
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Grant
    Filed: October 5, 2006
    Date of Patent: October 26, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
  • Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
    Patent number: 7812029
    Abstract: The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.
    Type: Grant
    Filed: February 8, 2008
    Date of Patent: October 12, 2010
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Ankush Argade, Donald G. Payan, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li
  • 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES
    Publication number: 20100197918
    Abstract: The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
    Type: Application
    Filed: April 16, 2010
    Publication date: August 5, 2010
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Rajinder Singh, Ankush Argade, Donald Payan, Susan Molineaux, Sacha J. Holland, Jeffrey Clough, Holger Keim, Somasekhar Bhamidipati, Catherine Sylvain, Hui Li, Alexander B. Rossi
  • PYRIMIDINEDIAMINE KINASE INHIBITORS
    Publication number: 20100179134
    Abstract: The present invention provides pyrimidinediamine compounds useful for inhibiting kinase activity, including the activity of polo-like kinase 1 (PLK1). Also provided are pharmaceutical compositions comprising these compounds and methods of treating diseases associated with kinase activity, in particular enhanced PLK1 catalytic activity, such as diseases associated with abnormal cell proliferation, including neoplastic disorders.
    Type: Application
    Filed: December 29, 2009
    Publication date: July 15, 2010
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Rajinder Singh, Andy Atuegbu, John Ramphal, Hui Li, Marina Gelman, Jeffrey Clough, Carlos Valdez, Somasekhar Bhamidipati, Sambaiah Thota, Darren McMurtrie
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20100158921
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: December 22, 2009
    Publication date: June 24, 2010
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Somasekhar Bhamidipati, Hui Li, Rajinder Singh, Vanessa Taylor, Jeffrey Clough, Darren McMurtrie
  • COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY
    Publication number: 20100152218
    Abstract: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
    Type: Application
    Filed: February 24, 2010
    Publication date: June 17, 2010
    Applicant: RIGEL PHARMACEUTICALS, INC.
    Inventors: Ankush Argade, Arvinder Sran, David Carroll, Jeffrey Clough, Kin Tso, Somasekhar Bhamidipati, Sambaiah Thota, Rajinder Singh, Vanessa Taylor, Hui Li, Esteban Masuda
  • 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
    Publication number: 20100152172
    Abstract: The present invention provides 3-hydroxyphenyl-2,4-pyrimidinediamine compounds of formula I, as well as related compositions and methods for treating a variety of autoimmune diseases.
    Type: Application
    Filed: December 18, 2009
    Publication date: June 17, 2010
    Inventors: Jeffrey W. Clough, Somasekhar Bhamidipati, Rajinder Singh, Esteban Masuda, Haoran Zhao